Younger Children More Likely to Experience Hearing Loss from Chemo Drug, Cisplatin

According to a new study by researchers at the University of British Columbia (UBC), a chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it. Cisplatin is a life-saving treatment for many children with cancer, but the study published today in Cancer shows that the hearing of…

Read More

Researchers Identify Genetic Variant Linked to Increased Hearing Loss Risk with Cisplatin Treatment

A University of Alberta research lab has helped identify a genetic variant that increases the risk of hearing loss in children with cancer who are treated with the widely used drug cisplatin. Amit Bhavsar, assistant professor in the Department of Medical Microbiology & Immunology and Canada Research Chair in Functional Genomic Medicine, led the U of A…

Read More
cisplatin hearing loss children risk

New Study Establishes First Benchmarks for Prevalence and Risk factors for Cisplatin-Induced Hearing Loss in Children

LOS ANGELES, CALIFORNIA — Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this medication, but until now, studies have been too small and too varied to accurately characterize this risk. Last week in The Lancet Child…

Read More
db-020 fast tracked fda

Decibel Therapeutics Announces DB-020 Granted Fast Track Designation by the FDA

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss,…

Read More

Indiana University Cancer Center Researcher Receives $5.7M Grant to Study Chemo-Induced Hearing Loss, Toxicities

INDIANAPOLIS, INDIANA —A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies.  An internationally recognized expert on cancer survivorship, Lois B. Travis, MD, ScD, leads the ongoing study that could lessen…

Read More
hearing loss prevention chemotherapy fennec

Development of Ototoxicity Drug, PEDMARK™, Faces Setback Following FDA Response

RESEARCH TRIANGLE PARK, NORTH CAROLINA — Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that it received a Complete Response Letter (CRL) on August 10, 2020 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity…

Read More
hearing loss prevention chemotherapy fennec

Fennec Announces FDA Filing Acceptance and Priority Review for Ototoxicity Drug, PEDMARK

RESEARCH TRIANGLE PARK, NORTH CAROLINA – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for the company’s New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate). PEDMARK is an investigational drug for the prevention of ototoxicity…

Read More
decibel therapeutics hearing loss treatment

Decibel Therapeutics Publishes Encouraging Results from Phase 1a Clinical Trial of DB-020

BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a development-stage biotechnology company developing novel regenerative therapeutics for hearing loss and balance disorders, announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs. DB-020 is being developed for the prevention of cisplatin-induced hearing…

Read More
chemo hearing loss tinnitus outcomes

Symptoms of Hearing Loss and Tinnitus May Indicate Poor Outcomes in Cancer Survivors

Development of chemotherapy-induced neuropathy (CIN), hearing loss, and/or tinnitus, in cancer survivors may be predictive of increased risk of severe symptom burdens and reduced quality of life (QoL), according to a study published in the European Journal of Oncology Nursing. All three conditions, CIN, hearing loss and tinnitus significantly detracts from patient QoL in numerous…

Read More